While doing some general searching, I came accross this...

While doing some general searching, I came accross this article...from 2002. That's right 13 years ago.

http://www.lifescientist.com.au/article/43408/gradipore_appoint_ceo_independent_chair/

I guess it speaks for itself, but here's a summary of interesting points, all Mr Manusu's words.

"Gradipore is on the hunt for a global CEO and an independent chair in a bid to become a "multi-billion dollar organisation," executive chairman John Manusu said today." - NuSep does not and has not had an independent chair in years. The chairman is...Mr Manusu himself.

"Manusu said that Gradipore...hired global search firm Heidrick and Struggles earlier this year to get advice on strengthening the company's executive team and board before it expanded." - Mr Manus has given us this line at NuSep every year for the last 3 years.

"We're setting ourselves a step above where we currently are," Manusu said. "We're in the same league as the Cochlears and the ResMeds - we don't see ourselves as a junior biotech." - In the same league?

"Gradipore is aiming to get US Food and Drug Administration approval for the Gradiflow, and make it a separation "gold standard" through strategic deals with several organisations and companies, including the Scottish National Blood Transfusion Service, Biomira, Bayer and Aventis." - How did those deals work out?

"But the company was also finalising a raft of new deals, Manusu said, with a range of companies, including a non-biotech. He said most of the deals would be able to be made public within the next month." - Haven't we herad this before somewhere more recent??

"The biotech market generally is not buoyant, but it's certainly not flat," Manusu said. "We've seen our sales really take off, largely at the expense of other players." - How did the sales work out in the end?

Mr Manusu's words are his own biggest critic.